Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18784256 | 0.91 | ALDH1A1 (0.44) | ALDH1A1TDP1GBA1SMN1; SMN2EPHX2 | |
| SCHEMBL11672013 | 0.89 | ALDH1A1 (0.47) | ALDH1A1TDP1GBA1SMN1; SMN2EPHX2 | |
| SCHEMBL18784323 | 0.89 | ALDH1A1 (0.47) | ALDH1A1TDP1GBA1SMN1; SMN2EPHX2 | |
| SCHEMBL18784316 | 0.89 | ALDH1A1 (0.47) | ALDH1A1TDP1GBA1SMN1; SMN2EPHX2 | |
| SCHEMBL3755541 | 0.85 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL3755536 | 0.85 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL17356736 | 0.85 | — | — | |
| SCHEMBL597505 | 0.84 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL6379260 | 0.79 | ALDH1A1 (0.46) | ALDH1A1TDP1GBA1SMN1; SMN2SPHK2 | |
| SCHEMBL15962846 | 0.78 | SMN1; SMN2 (0.47) | ALDH1A1TDP1GBA1SMN1; SMN2SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114903-B2 | Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids | BTG INTERNATIONAL LIMITED (GB) | 2012-02-14 | — | — | US | claimed |
| EP-1853254-B1 | CYTOKINE MODULATORS USING CYCLIC GLYCERIDES OF ESSENTIAL POLYUNSATURATED FATTY ACIDS | BTG INT LTD (GB) | 2010-12-08 | — | — | EP | claimed |
| US-20100297196-A1 | Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids | BTG INTERNATIONAL LIMITED (GB) | 2010-11-25 | — | — | US | claimed |
| US-20090137660-A1 | Cytokine Modulators Using Cyclic Glycerides of Essential Polyunsaturated Fatty Acids | BTG INTERNATIONAL LIMITED (GB) | 2009-05-28 | — | — | US | claimed |
| EP-1853254-A1 | CYTOKINE MODULATORS USING CYCLIC GLYCERIDES OF ESSENTIAL POLYUNSATURATED FATTY ACIDS | BTG International Limited (GB) | 2007-11-14 | — | — | EP | claimed |
| WO-2006092623-A1 | CYTOKINE MODULATORS USING CYCLIC GLYCERIDES OF ESSENTIAL POLYUNSATURATED FATTY ACIDS | BTG INTERNATIONAL LIMITED (GB) | 2006-09-08 | — | — | WO | claimed |
| US-8114903-B2 | Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids | BTG INTERNATIONAL LIMITED (GB) | 2012-02-14 | — | — | US | disclosed |
| EP-1853254-B1 | CYTOKINE MODULATORS USING CYCLIC GLYCERIDES OF ESSENTIAL POLYUNSATURATED FATTY ACIDS | BTG INT LTD (GB) | 2010-12-08 | — | — | EP | disclosed |
| US-20100297196-A1 | Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids | BTG INTERNATIONAL LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20090137660-A1 | Cytokine Modulators Using Cyclic Glycerides of Essential Polyunsaturated Fatty Acids | BTG INTERNATIONAL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| EP-1853254-A1 | CYTOKINE MODULATORS USING CYCLIC GLYCERIDES OF ESSENTIAL POLYUNSATURATED FATTY ACIDS | BTG International Limited (GB) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006092623-A1 | CYTOKINE MODULATORS USING CYCLIC GLYCERIDES OF ESSENTIAL POLYUNSATURATED FATTY ACIDS | BTG INTERNATIONAL LIMITED (GB) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137660-A1 | Cytokine Modulators Using Cyclic Glycerides of Essential Polyunsaturated Fatty Acids | IL5, IL15, IL2 | ALDH1A1 1563/4885TDP1 4882/4885GBA1 422/4885 |
| US-20100297196-A1 | Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids | IL5, IL2, IL15 | ALDH1A1 2185/4885TDP1 4883/4885GBA1 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.